Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Merrimack Pharmaceuticals' stock was trading at $13.41 at the start of the year. Since then, MACK stock has increased by 9.5% and is now trading at $14.68.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MACK earnings forecast.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.

Merrimack Pharmaceuticals shares reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.